Stockscreener 앱 받기
16.34
1.92%
-0.32
시간 외 거래:
16.34
Viatris Inc 주식(VTRS)의 최신 뉴스
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Should Value Investors Buy Viatris (VTRS) Stock? - Yahoo Finance
Positive IgA Nephropathy Data And Yen Loan Recast Could Be A Game Changer For Viatris (VTRS) - simplywall.st
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 - AOL.com
Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move? - Yahoo Finance
Viatris Q1 2026 slides: earnings beat drives shares higher - Investing.com
Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results - Yahoo Finance
Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now - Insider Monkey
Viatris stock hits 52-week high at $16.63 - Investing.com
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Inc. Class Action: The Gross Law Firm Reminds Viatris In - GuruFocus
VTRS Stock Price and Chart — NASDAQ:VTRS - TradingView
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
A Look at Viatris Inc (VTRS) After 3.1% Gain -- GF Value $11.02 vs Price $16.70 - GuruFocus
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris (VTRS) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Viatris Refinances $247.7 Million Term Loan - Moomoo
VTRSViatris Inc Dividends - Finviz
Form 4 Viatris Inc For: 1 July By Investing.com - Investing.com Canada
Viatris (VTRS) director David S. Simmons granted 2,362 deferred stock units as fees - Stock Titan
Viatris (VTRS) director takes 2,756 deferred stock units instead of cash fees - Stock Titan
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris to Report Second-Quarter 2026 Financial Results on Augus - GuruFocus
ViatrisEnters Amended And Restated Term Loan Credit Agreement On July 1, 2026SEC Filing - TradingView
Viatris Secures ¥40 Billion Three-Year Term Loan With Mizuho to Refinance 2021 Facility - TradingView
Viatris (NASDAQ: VTRS) signs ¥40B three-year unsecured term loan deal - Stock Titan
Viatris Inc Enters Into Amended and Restated Term Loan Credit Agreement for JPY 40,000,000,000 Senior Unsecured Term Loan Facility - marketscreener.com
Lost Money on Viatris Inc. (VTRS)? Join Class Action Before June 3, 2025Contact Levi & Korsinsky - The National Law Review
The Bull Case For Viatris (VTRS) Could Change Following Positive Japan Phase 3 Data For VR-205 - simplywall.st
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Securities Fraud Class Action Filed Against Viatris Inc. (VTRS) Levi & Korsinsky Reminds Investors of June 3, 2025 - The National Law Review
Viatris reports positive phase 3 results for IgAN drug in Japan By Investing.com - Investing.com India
(VTRS) Risk Channels and Responsive Allocation - Stock Traders Daily
How is Viatris’ stock performance compared to other healthcare stocks? - MSN
Viatris reports positive Japanese phase 3 results for Nefecon in IgAN - MSN
Viatris reports positive phase 3 results for IgAN drug in Japan - Investing.com South Africa
Viatris' VR-205 Meets Primary, Key Secondary Endpoints in Japanese Phase 3 Trial in Kidney Disease - marketscreener.com
Viatris (VTRS) Reports Positive Phase 3 Trial Results for VR-205 - GuruFocus
Viatris kidney drug VR-205 cut protein in urine 33.75% in Japan - Stock Titan
Viatris Inc. (VTRS) Stock Analysis: Exploring a 9% Upside Potential Amid Diverse Healthcare Offerings - DirectorsTalk Interviews
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy - PR Newswire
Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – VTRS - The National Law Review
Viatris Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVTRS - The National Law Review
VTRS LAWSUIT ALERT: Levi & Korsinsky Notifies Viatris Inc. InvestorsLead Plaintiff Deadline June 3, 2025 - The National Law Review
Join Class Action to Recover Losses from Viatris Inc. (VTRS)Contact Levi & Korsinsky Before June 3, 2025 - The National Law Review
Enterprise value to EBITDA forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Viatris interim CFO Paul Campbell sells $809,784 in stock By Investing.com - Investing.com South Africa
Viatris interim CFO Paul Campbell sells $809,784 in stock - Investing.com UK
Form 4 Viatris Inc For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Price to earnings forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Enterprise value to EBIT forward of Viatris Inc. – NASDAQ:VTRS - TradingView
1.30%
0.34%
자본화:
|
볼륨(24시간):